AOD-9604 Half-Life Calculator
AOD-9604 is a fragment corresponding to the C-terminal region of human growth hormone, developed on the premise that the fat-metabolism activity could be separated from growth hormone's other effects. Its half-life is measured in minutes.
Half-life 3 min · peaks at 2 min
Every 24 hours.
Half-life
Left at next dose
AOD-9604 · once daily · levels plateau after ~15 min
Steady-state peak
0.06 mg
Steady-state trough
0 mg
Accumulation
None
At once daily, each dose has essentially cleared before the next one — levels don't accumulate, they repeat the same rise and fall. Clearance after a dose takes about 15 min.
This is a modelled estimate of relative levels from published half-life and time-to-peak figures — not a measured blood concentration. Individual pharmacokinetics vary.
Based on a published AOD-9604 half-life of about 3 min. The chart models RELATIVE levels from a unit dose — enter your own figures to see the shape. It is not a dose recommendation.
Never do this math twice.
The Pep AI app remembers your vials and doses, shows an interactive syringe you draw to, counts down the doses left in each vial, and reminds you when it's time. Free on iOS and Android.
What a 3 min half-life means in practice
A half-life of 3 min against once daily dosing means each dose has essentially cleared before the next arrives. That shapes the curve in three ways:
1. One half-life
Half the dose is gone after 3 min. After two half-lives 25% remains, after three 12.5%.
2. What's left at the next dose
Dosing once daily means the next dose lands 24 hours later, with about 0% of the previous one still present.
3. Accumulation and plateau
Almost nothing carries over, so levels don't accumulate — each dose repeats the same rise and fall, clearing in about 15 min.
Worked example
AOD-9604 has a half-life of 3 min. Dosing once daily, the next dose arrives 24 hours later with about 0% of the previous one still on board. That's little enough that levels don't build up: each dose rises and falls on its own, clearing in about 15 min.
A fragment, and a development history worth knowing
AOD-9604 corresponds to residues 176 to 191 of human growth hormone. The rationale was that this region carries the lipolytic activity while the growth-promoting and glucose effects sit elsewhere in the molecule — an attractive hypothesis that motivated clinical development.
That development did not produce an approved product. Trials did not establish efficacy sufficient for approval, which is a substantive result rather than an administrative one: the compound was tested in humans and the outcome was not positive enough to proceed. That history is frequently omitted from summaries, which tend to present the original hypothesis as though it were the finding.
Frequently asked questions
This calculator is provided for informational and educational purposes only and is not medical advice. Always confirm dosing with a qualified healthcare professional and double-check your own measurements before administering anything.
Built by the Pep AI team.